Recombinant Zebrafish BACE1

• Cat.No.: BACE1-11726Z
• Product Overview: Recombinant Zebrafish BACE1 full length or partial length protein was expressed.

Specification

• Source: Mammalian Cells
• Species: Zebrafish
• Tag: His
• Form: Liquid or lyophilized powder
• Endotoxin: < 1.0 eu per μg of the protein as determined by the LAL method.
• Purity: >80%
• Notes: This item requires custom production and lead time is between 5-9 weeks. We can custom produce according to your specifications.
• Storage: Store it at +4 oC for short term. For long term storage, store it at -20 oC～-80 oC.
• Storage Buffer: PBS buffer

Gene Information

• Gene Name: bace1 beta-site APP-cleaving enzyme 1 [ Danio rerio (zebrafish) ]
• Official Symbol: BACE1
• Gene ID: 403005
• mRNA Refseq: NM_205704
• Protein Refseq: NP_991267
• UniProt ID: Q6NZT7

Reviews

07/27/2020

Such support ensures researchers have access to reliable tools and expertise, facilitating their investigations into the functions, mechanisms, and disease relevance of BACE1 protein.

12/23/2019

A manufacturer can serve as a collaborative partner, engaging in discussions, and exchanging knowledge with researchers.

09/30/2019

Using BACE1 protein in trials provides advantages such as its involvement in cellular processes and its disease associations.

Q&As

Are there any potential side effects associated with BACE1 inhibition?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

How is BACE1 linked to Alzheimer's disease?

BACE1 is implicated in Alzheimer's disease as it initiates the cleavage of APP, leading to the formation of beta-amyloid plaques, a hallmark of the disease.

How can BACE1 inhibitors potentially benefit Alzheimer's patients?

BACE1 inhibitors may slow down or prevent the accumulation of beta-amyloid plaques, potentially delaying the progression of Alzheimer's disease.

Are there any ongoing clinical trials involving BACE1 inhibitors?

Yes, several clinical trials are underway to assess the safety and efficacy of BACE1 inhibitors in treating Alzheimer's disease.

Are there clinical applications of BACE1 inhibitors?

Yes, BACE1 inhibitors are being explored as potential therapeutic agents for Alzheimer's disease to reduce the production of beta-amyloid peptides.